Northway Biotech Launches Full-Service Viral Clearance Studies, Delivering Results Faster Than Industry Standards
With six newly established, identical BSL-2 laboratories now operational, biologics CDMO Northway Biotech can conduct VCS programs for up to six clients simultaneously, significantly alleviating current market bottlenecks
VILNIUS, LT / ACCESS Newswire / May 5, 2025 / Northway Biotech, a biopharmaceutical contract development and manufacturing organization (CDMO), today announced the expansion of its protein-based and gene therapy service offerings with the addition of Viral Clearance Studies (VCS) capabilities. This strategic growth follows the opening of Northway Biotech's new Gene Therapy Center with dedicated cGMP facilities for virus-related projects.
With six newly established, identical BSL-2 laboratories now operational, Northway Biotech can conduct VCS programs for up to six clients simultaneously, significantly alleviating current market bottlenecks. Additionally, the company has expanded its capabilities to perform GMP-compliant manufacturing and testing under BSL-3 conditions, further strengthening its service offering across gene therapy and broader biologics development.
Viral Clearance Studies are now offered both as part of Northway Biotech's integrated CDMO programs and as a standalone service. This flexibility allows external clients to access VCS expertise independently, without requiring a manufacturing agreement.
Accelerated Delivery Timelines - Over One Month Faster Than Industry
Leveraging expanded infrastructure and integrated analytical capabilities, Northway Biotech is positioned to deliver Viral Clearance Studies substantially faster than the current industry standard. Comprehensive studies, assessing viral removal and inactivation, can now be completed with final regulatory-compliant reporting in under 10 weeks from initiation of project design when two model viruses are employed, and within 12 weeks when four model viruses are used.
"Our expansion into Viral Clearance Studies is a natural extension of our CDMO services, enabling us to manage these critical studies in-house and significantly reduce project timelines for our clients," said Prof. Vladas Algirdas Bumelis, CEO of Northway Biotech. "By investing in state-of-the-art BSL-2 and BSL-3 facilities, expanding technical capabilities, and further strengthening our scientific teams, we are uniquely positioned to deliver high-quality VCS data faster - a key advantage for clients advancing through clinical development and regulatory approval."
For more information on Northway Biotech's Viral Clearance Study processes, service offerings, and delivery timelines, please complete the contact form to connect with the Northway Biotech team.
About Northway Biotech - https://www.northwaybiotech.com
Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced and professional team executes projects at every stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company's extensive expertise and vertically integrated service offering enables rapid execution of multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development, and commercial manufacturing. Northway Biotech is a privately owned company founded in 2004 and operates locations in Vilnius, Lithuania; London, United Kingdom; and Waltham, MA, USA.
Media & Business Contact:
Prof. Vladas Algirdas Bumelis
CEO and Chairman of the Board
Northway Biotech
vladas.bumelis@northwaybiotech.com
Contact Information
Vladas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com
SOURCE: Northway Biotech
View the original press release on ACCESS Newswire
Northway Biotech
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Loar Holdings Inc. Announces Date and Time for First Quarter 2025 Earnings Conference Call6.5.2025 08:30:00 CEST | Press release
WHITE PLAINS, NY / ACCESS Newswire / May 6, 2025 / Loar Holdings Inc. (NYSE:LOAR), will report Q1 2025 earnings before the market opens on Tuesday, May 13, 2025. A conference call will follow at 10:30a.m., Eastern Time. To participate in the call telephonically please dial +1 877-407-0670 / +1 215-268-9902. International participants can find a list of toll-free numbers here. A live audio webcast will also be available at the following link as well as through the Investor section of Loar Holdings website; https://ir.loargroup.com The webcast will be archived and available for replay later in the day. About Loar Holdings Inc. Loar Holdings Inc. is a diversified manufacturer and supplier of niche aerospace and defense components that are essential for today's aircraft and aerospace and defense systems. Loar has established relationships across leading aerospace and defense original equipment manufacturers and Tier Ones worldwide. Contact Ian McKillop Loar Holdings Inc. Investor Relations
Global Survey Reveals Urgent Gaps in Awareness, Access, and Treatment for Hepatitis D6.5.2025 08:00:00 CEST | Press release
LONDON, UK / ACCESS Newswire / May 6, 2025 / A new report released today by the World Hepatitis Alliance (WHA) reveals widespread knowledge gaps, inequities in access, and critical systemic barriers impeding the global fight against hepatitis delta. Also known as hepatitis D, hepatitis delta is a severe liver disease affecting an estimated 12 million people worldwide. It occurs in people living with hepatitis B, leads to faster disease progression, and significantly increases the risk of liver cancer and death. The Hepatitis Delta Global Landscape Survey collected responses from 583 individuals across 102 countries, providing the most comprehensive picture to date of global stakeholder perspectives on awareness, testing, and treatment access around hepatitis delta. Key Findings: There are pronounced regional variations in reported availability and accessibility of hepatitis delta testing and treatment. Even where hepatitis delta testing and treatment are reported to be available, acces
Camino Announces Exploration Results at Los Chapitos and Further Exploration Plans in Peru6.5.2025 06:00:00 CEST | Press release
VANCOUVER, BC / ACCESS Newswire / May 6, 2025 / Camino Minerals Corporation (TSXV:COR)(OTC PINK:CAMZF) (WKN: A116E1) ("Camino" or the "Company") is pleased to announce exploration results at its Copper-Silver stratabound Los Chapitos copper project ("Los Chapitos" or the "Project"), including drilling and additional mapping, trenching, and sampling along both the La Estancia and Diva copper mineralized trends. The Company is targeting large-scale disseminated manto-type copper-silver mineralization to support resource delineation studies at Los Chapitos. Camino and its partner Nittetsu Mining Co., Ltd. ("Nittetsu") plan to commence the next phase of drilling in the second half of 2025. The Los Chapitos copper project is located near the coastal city of Chala in the department of Arequipa in Peru. Juan Carlos Castelli, Consulting Geologist from Chile, said "the Los Chapitos property is inside the northern continuation of the metallogenic Cu-Ag belt defined in Northern Chile, with operat
OMP Achieves Top Two Rankings in Four Use Cases in the 2025 Gartner Critical Capabilities for Supply Chain Planning Solutions Report6.5.2025 05:00:00 CEST | Press release
ANTWERPEN, BE / ACCESS Newswire / May 6, 2025 / OMP, a global leader in supply chain planning solutions, has achieved four second-highest scores across five Use Cases, evaluated in the 2025 Gartner® Critical Capabilities for Supply Chain Planning Solutions report. This report, a companion to the Gartner Magic Quadrant™, assesses the vendors of the SCP solutions evaluated in this research. This recognition follows OMP's recent position as highest on the Ability to Execute axis in the 2025 Gartner Magic Quadrant for Supply Chain Planning Solutions - marking the tenth consecutive time OMP is named a Leader. Consistent strength across real-world planning challenges The Critical Capabilities report evaluates 20 vendors on 15 key capabilities across five SCP Use Cases. We believe OMP's scores, particularly in supply planning, decision/plan alignment, and the breadth of resource types, demonstrate its strong performance in these critical areas. "Supply chains today need real solutions that de
Black Iron Congratulates the U.S. and Ukraine on Their Minerals Deal and Aims to Help Pave the Way With Its Highly Advanced Ukraine New Mining Project5.5.2025 07:16:00 CEST | Press release
U.S. and Ukraine entered into a landmark agreement to jointly develop Ukraine's vast mineral resources. Black Iron (TSX:BKI) is developing the most advanced project to construction in Ukraine. Black Iron's successful construction and operation will create a development roadmap for investments under the U.S. - Ukraine Minerals Agreement. TORONTO, ON / ACCESS Newswire / May 5, 2025 / Black Iron Inc. ("Black Iron" or the "Company") (TSX:BKI)(OTCPK:BKIRF)(FWB:BIN) congratulates Ukraine and the United States governments on signing a landmark agreement to jointly develop Ukraine's vast mineral resources - a strategic move designed to accelerate post-war reconstruction and reduce global dependency on hostile-state supply chains. With potentially trillions of dollars worth of untapped mineral resources and growing Western support, Ukraine is positioning itself as a future powerhouse in the critical minerals sector. The challenge is that there hasn't been a new large-scale mine constructed in U
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom